Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-10
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Welcome, everyone. Yatin Suneza from Guggenheim. My pleasure to host Craig Parker, the CEO of Surosan here. We will be chatting for the next, let's say, 25, 30 minutes. Craig, thank you so much. We always appreciate your presence and you coming, spending time with us. Why don't you make some opening comments? You know, there were some key updates that you provided yesterday on the earnings release, maybe recap that. And obviously, we have a lot to discuss between, you know, your program and some of the stuff that is happening on the competitive dynamics. So why don't you make some comments?
Yeah, it's a very exciting time for Wnt Biology, exciting time for retina broadly, retinal vascular diseases broadly. So the background of Surizen is we actually started as a Wnt Biology-focused company. We discovered the multifunctional antibodies that we've been pursuing. And have looked at a number of different areas and arrived at targeting the specific receptors that we're targeting and that the Merck molecule targets because of some really compelling human genetics, some childhood retinal diseases that illustrate how important these targets in this pathway are in preserving normal retinal vessel function. So we made an antibody that we thought really accomplished, you know, really a number of key objectives in treating the disease. And I think we'll talk about the Merck data, but, you know, the combination of the clinical benefit that's been shown with all the anti-VEGF molecules combined now with the clinical benefit that's been shown with targeting Wnt signaling. And we're activating Wnt signaling with that portion of the molecule, that those really look like the two best mechanisms to treat retinal vascular diseases, at least diabetic macular edema. So, that's the foundation for our approach, was to take our knowledge of Wnt signaling, combining it with, you know, what's been proven to be very efficacious in these retinal vascular diseases into one molecule.
Got it. I think it would be helpful to put in perspective on what is going on in that space. Obviously, at the AAO, Mark Brunello data got presented. There was a lot of focus going into it. So what were the key learnings for you? Maybe put in perspective the efficacy and both the safety and the efficacy profile that we saw with the Mark Molecule.
Yeah, so this was a large Phase III, nearly 1,000-patient Phase III trial. Patients had diabetic macular edema. About three-quarters of them were treatment-naive diabetic macular edema patients. In this study, they got randomized to either Lucentis, which is one of the older VEGF antibody fragments, or one of two doses of what's now called Remig-Remig. People also know it as MK3000 or Restoret. This is there. Frizzled for LRP5 targeted Wnt agonist. And really for the first time ever with something other than a VEGF mechanism, what they showed was you can get a VEGF-like efficacy, and that's measured in a couple of ways that I'll come back to. So VEGF-like efficacy. And that really alone is quite a breakthrough for the field, that a non-VEGF mechanism could show this kind of clinical benefit. Others have been tried alone, like ANG2 alone, IL-6 alone. None of these have shown that magnitude of benefit. And on the safety side, other than something called proliferative diabetic retinopathy, where they saw higher rates, it was very safe, so no other intraocular inflammation. So I think that's really important for the field. Some other aspects of the data that I think were very important, visual acuity was correlated with drying, and that's something we did not know with Wnt signaling, whether those would be as well correlated as they are with anti-VEGF therapy. The onset of clinical benefit was very rapid. It was as rapid as VEGF. That's something else we didn't know about Wnt signaling, that it could result in very rapid retinal drying. So that's really encouraging for us. And then we have an anti-VEGF component to our molecule and the way you treat proliferative diabetic retinopathy and vitreous hemorrhage, which is what they saw, is with anti-VEGF molecules. So, you know, when we left, literally walked out. Of the theater where the data was presented, we happened to talk to a couple of our clinical advisors. You can see who they are on our website, and they all said, like, this is the perfect landscape for you. Like, Wnt works really well, and part of your molecule is going to treat the one potential liability of the Merck molecule, which is proliferative diabetic retinopathy.
Got it. So with regard to, again, going into the study, there were two focuses, right, or two or three things people were focused on. One was obviously on the safety side, so on the PDR adverse rate, do you get a sense that that has been put to, or that is behind us now, like people are not really focusing on, is it more of a, maybe talk about that, and then on the efficacy side, we do get question on some of the differences, you know, it's about, let's say, three-letter difference, how meaningful is that?
Yeah, I mean, so on the proliferative diabetic retinopathy side, I think if you, when we talk to our clinical advisors and our head of clinical development is a retinal specialist, I think they would all tell you that in a 12-month study of diabetic macular edema patients, you would expect to see an evolution of diabetic retinopathy of non-proliferative converting to proliferative DR. The question is, what rate does that occur if you don't have VEGF treatment? Merck, the presenter for Merck, highlighted a couple of other studies, a very old study that was done when you could do sham injections, and then a more recent study that used laser photocoagulation. You know, those rates were 11 to 22% at 12 months, so they're 6.1 and 6.7 was below that, and so I think most retinal specialists would tell you the PDR was not the result of activating wind signaling, causing it, it was inadequate control of PDR, and anti-VEGEP happens to control this vitreous hemorrhage and PDR very well, so I think there was a clear consensus that That rate was lack of adequate control of PDR. You know, they have a second parallel study that's going to get reported around February called Barolo. I would expect that we and others will be looking to see whether those rates are about the same or whether for some reason these 6% were outliers one way or the other. So as of now, again, we control that with the anti-VEGF portion of our molecule, And I think it'll be important to see what that rate is in the second study. You know, with respect to the efficacy... I mean, you've looked at the results of these studies. Even thousand patient studies are highly variable. We actually had a statistician go through all the published data for Flibercept, Ferisimab, and Lucentis. And, you know, the mean varies by study, but, you know, it's generally about nine letters for VEGF-based molecules. The standard deviation is seven and a half letters. So, you know, a two-letter difference is probably not an actual true difference in efficacy, and Lucentis outperformed all of the previous Phase III studies that have been done with Lucentis. So, Lucentis historically had about an 8.8 or 8.5-letter benefit, so its 10.7 or what I think it was, or 11.1-letter benefit was larger than had been ever seen with Lucentis. So I'm not sure that those are meaningful comparisons to say that, you know, went slightly underperformed because Lucentis, compared to historical data, outperformed.
Outperformed, yeah, yeah, very, very good point.
And the same is true, actually, of central subfield thickness, which is one of these measurements of retinal drying. We had a statistician do the same exercise. If the mean across phase three studies was 150 microns, the standard deviation was 80. Oh, wow. The standard deviation was 50% of the treatment effect for CST. So again, these 20 micron differences are probably not true differences in the efficacy.
Got it, got it. And then going back on the PDR adversity, I think it was also comforting to see there was no dose response. I think both arms were similar.
Right, yeah. I mean, there didn't seem to be a dose response for any outcome measurement with, at least with 0.5 and 0.8 milligrams. And they had previously described that in their phase one, two, they didn't see a dose response, even with a wider range of doses.
Got it, got it, got it. So this was Brunello. Now, what is your molecule? How it is differentiated? Explain to us what are these two different arms of the molecule.
I mean, so the most easily identifiable difference is they have no anti-VEGF components on their molecule. The Wnt portion of the molecule, we are targeting the same receptor and co-receptor, so we're both targeting Frizzled4 and LRP5. I won't get into sort of the inside baseball of antibody fragments and the differences between diabodies and VHH fragments, but we're both targeting the same receptor and co-receptor. So if you think about, is the pharmacology of Wnt signaling different, the answer is no, it's probably the same. The downstream effects are the same. But what we also know from our molecule is it's more potent in cell-based assays, and it's more potent in animal models of retinopathy than Remig-Remig, at least what we've made from what's in the published patent with the sequence of Remig-Remig. So we do seem to have greater potency in cell-based assays and in animal models for the Wnt portion of the molecule. Now, you know, they did not have a dose response. Do we know that that's going to translate to efficacy benefits? No, but again, in animal models, we do see a dose response with our molecule, and we do see differences.
Got it. And what about the VEGF portion of it? Like, is it ILEA or, like, what is it? It is, yeah.
So it's actually the same decoy receptor sequences that are used in ILEA. And when we designed the molecule, one of the objectives was to try to retain the same VEGF binding characteristics of ILEA, which we've been able to do.
Okay, okay. So now you have submitted the IND, and yesterday you actually announced that you are increasing the size of the study. So can you walk us through what you are doing, what are these two studies or, you know, the duet study, what is the cadence of the data, what type of patient you're going to get?
Yeah, so we're pursuing, as Merck did, diabetic macular edema as the initial indication. Probably not going to have time to talk about the biology of some of the other potential indications, but there is a clear biological rationale of other retinal vascular diseases like wet AMD, retinal vein occlusion. And others. The biology in the retinal vessels is quite elegant that Frizzled is involved in normal retinal vessel development, normal retinal vessel function, and the barrier function of these what are called tight junctions. So that's one reason for pursuing diabetic macular edema as an initial indication. It's also probably less well served by anti-VEGF molecules. So the percent of patients, for example, who achieve complete dryness in DME is much lower than in wet AMD. So if you're thinking about where might I detect a signal of differential efficacy, DME is probably a better background to do that. So this study is in DME. The initial SAD portion is in treatment experience DME because with a first in human, it's easier to enroll those patients, easier ethically for investigators to enroll patients. Compared to treatment naïve patients who have clear treatment choices with the currently available drugs. The announcement we made was for part two of this study that we're going to expand it from about 60 patients total. So about 150 patients total, and I think, you know, we're going to do what I think people have said is, you know, I don't know if bold is the right word, but, you know, we think this can be the best drawing agent, and we want to see if there are indications of that in this phase two portion of the study. So we're going up directly against Vibaismo. So it'll be 50 patients per cohort, two dose levels that we'll determine from the phase, the part one portion of the study. 50 patients on Vibaismo, 50 patients on each of two dose levels of 8141. I mean, as with any early studies, safety is the primary outcome, but we'll use the same kind of imaging techniques that are used in phase three trials to measure retinal fluid. We'll use the same techniques that are used to measure visual acuity. So we think that we could not, it's not powered to detect statistical differences, but directionally, we think we could see some improvements in drawing and visual acuity versus Vavismo. The 50 patients, there's no magic number. It's not that it achieves specific statistical power at that. You know, it's sort of more than 20 is better. We were able to raise some money, which we announced yesterday, through an ATM to be able to fund expanding the study. And as I mentioned, a competitor has been able to take a data set of about that size and apparently successfully argue to FDA that they only need to do a single dose level in phase three, which really makes a phase three program a lot more streamlined.
I see, I see, I see. So, yeah, I think that makes sense now. You have 50 patients, if you can pick a dose. Yeah, if you pick one dose from that, yeah, exactly.
And that portion of the study will be three doses with another four months of follow-up. So, you know, with all these mechanisms now, this was an important, I think, observation from the Merck study is, like VEGF, these molecules achieve close to their peak benefit at 12 weeks. So that is a relevant time point to look at efficacy, and both visual acuity and retinal drying.
Okay, so you should be, and you should be able to see, because the one, the other thing that we don't know about your molecule or the Merck molecule is also the frequency that you can give, Merck is giving it on a monthly basis, but you can check off treatment durability.
Yeah, so we'll continue to observe patients for four months, and then, you know, make a commitment to a phase Phase 3 design. Now, one important aspect of a Phase 3 design that I think Roche really showed was you want to enable use and reimbursement for many different regimens. So I think committing to a single regimen in Phase 3, even if you had a high level of confidence that you could get to, say, every four months, you might not want to do that in your Phase 3 because if a physician wants to use it more frequently, they may not get reimbursed.
Yeah, that's true. That is true. So what is the timeline for this SAD and then a Part 2 study? When do you expect to initiate the SAD? At what time point you'll be able to, or after how many doses, you'll be able to move to the Part 2 of the study?
So we announced yesterday that we dosed the first patient in the SAD portion. We have only disclosed that we'll have data from that portion of the study in 2027. We haven't given guidance on exactly when the full part two data would be available. That first portion is a single dose with 12 weeks of observation after that. You might think, well, you're really going to get insights into the clinical benefit and the durability. And if you look at other data sets, the answer really is yes. At four weeks, you see a pretty dramatic improvement. In fact, almost half of the ultimate peak improvement you can see by four weeks, and then we know from PK modeling that the drug is still around long after even a month, so a 12-week durability assessment might be meaningful as well. So that would be the data set that we would have in 2027. We haven't disclosed exactly the absolute starting dose, but it'll be a couple of cohorts likely. Again, one dose, 12 weeks of follow-up, and the design is at least three patients per cohort. Yeah, all experienced patients.
All experienced patients, yeah. Okay, and then you'll decide the two doses based on that data.
Yeah, we would take the two highest tolerated, this has become a pretty common design element in these Phase I and II trials, is take the two highest doses into this expansion phase, which we're calling the Part II of the study.
Yeah. So you mentioned about the choice of Vibismo. Yes, I think it's a bold choice. Why? Like, there must be something underlying. I mean, you must have a thesis for you to feel confident that, look, you know, we're going to go after the agent that dries the best.
Yeah. Yeah. I mean, so the foundation and vision, it's hard not to make puns in this disease area, is for this to be the best drying agent. And Vibaismo was able to show that versus VEGF alone. And that was with a backbone of one component that had shown really minimal, if any, differences as a monotherapy. So ANG2 is a monotherapy. There's never been a robust data set published, but it doesn't seem to add much as a monotherapy, and yet there's additive benefit. We know from data set with combining IL-6 inhibition with VEGF inhibition, even though IL-6 alone is probably half the benefit of Wnt alone, that there's incremental benefit, there's additive benefit on top of VEGF. And so that was really the foundation of this approach, was take the two best mechanisms and combine them, and our preclinical data actually supports a synergistic effect, not just an additive effect, but we would hope in humans to at least have some additive benefit from those two, and if we do, we should see at least numerical indications of that against provisimo, and that's become the standard of care. And so a lot of people have asked us, why don't you go up against ILEA? It'll be easier to beat. You want to make sure you have a positive study. But, you know, the intent with this molecule is to really be a better agent, not, you know, just be another agent.
Yeah, yeah, helpful. What about AMD or wet AMD? What is the path there? Obviously, Mark is going in AMD as well. Just curious, like how strong is the biology there? I mean, at least with VEGF on board, you should not have the risk in that indication. But how do you think?
Yeah, I mean, as I mentioned about why do DME first, you know, if you just look at the published data and what's even in the label for Vibaismo, for example, you know, a very high proportion of wet AMD patients get what's referred to as completely dry. So no evidence of macular edema. And so it just is numerically a more challenging. That's a great indication to try to show some differentiation. Now, that doesn't mean you won't get used there if you have a molecule that's better in DME and roughly comparable in wet AMD. And that's actually the profile of Vibismo. And I think if you asked a retinal specialist, you know, why do you choose Vibismo for wet AMD? They'll say, well, it's a better drying agent. So where is it a better drying agent? Well, in DME. So why are you using wet AMD? Well, it's just, it's my drug to use in retinal vascular diseases. So success in DME, I think was a clear case study that. That translates to uptake in wet AMD. Should it be at least as good in wet AMD, you know, you already alluded to there's VEGF on board, but there's actually is interesting biology in these vessels at the back of the eye that are what are implicated in wet AMD. So these are called the choroidal vessels or the chorocapularis. There's a Howard Hughes investigator at Hopkins who's published probably the most in this field that if you knock out Wnt in these vessels, that you do get more leakage. And if you upregulate Wnt in these vessels, that you can reduce that leakage. So there's clearly Wnt biology going on in this network of vessels, which is quite different than the retinal vessels that are involved in DME. It's just not quite as elegant biology, I would say, as is the case in retinal vessels. But there's definitely a biological rationale. We have data in models of wet AMD. To show that it does confer benefits over VEGF alone.
Got it. Where are you on the tox work? Because I think after the phase two, you would, you know, as you go into phase three, the tox work needs to be done. So that's one. Yeah. And then you mentioned about the editing effect. Like, what is the end goal? What is the regulatory part? It's most likely going to be a non-inferiority study.
Yes. Yeah, so we haven't disclosed the details of the tox, but yes, you're quite right. To do a phase three, you need to do a six-month, what would be considered a chronic tox study. And to start our current SAD, you would only need a one-month study. So obviously, we wanted to get started as quickly as possible. We're not going to go into the details of all the tox studies that we've completed or planned, but yes, you'd need a six-month study completed and reports to start your phase three.
And then the phase three, like what is the regulatory path? Do you need to show additive effect when you are going for non-inferiority?
Yeah, so, you know, again, sort of falling back on Vibaismo as a case study. They showed non-inferiority on visual acuity and then some drying benefits in particular. The percentage of patients with no intra-retinal fluid is quite prominent in their promotional material, and I think what contributes to it being perceived as the best drying agent. Now, no one's done this successfully, but there is guidance on superiority in these Phase III trials, which is proportion of patients with a 15-letter gain, so if you have a statistically higher proportion of patients, or a lower proportion of patients with a 15-letter loss. I think people just haven't seen enough additive benefit earlier, like in a phase two trial, to want to go after that. So non-inferiority, it turns out, allows you to do a smaller study. Even if you had an incremental visual acuity benefit, you'd have to do a very large study to power it to show superiority. Got it. That doesn't mean that can't be a secondary. Sure.
Sure. I mean, you can assess that. Yeah. Okay. Any update on the second molecule that you have and also the Boringa-Linga-Haim molecule?
Yeah, so no update on the BI molecule. Once we reached a point after, I think, a very fruitful research collaboration, it's in their hands now, and they're not required to give us prospective reports on what they're doing or when it's going to happen. And so, you know, we, last time we reported any progress was when they started phase one, and they owed us a milestone, so that was material for us, so we disclosed it. But, you know, they're a private company, and there's not much public disclosure, nor to us, about what they're doing. So we just know it's in the clinic now. Sorry, 8143. Yeah, 8143. So this is a combination, really, of 8141 plus IL-6 inhibition. You know, we want to be thoughtful about having, you know, I think a capital efficient and complementary strategy with those two molecules. So, you know, if we were a very big company that had all the time in the world and a lot of money, we might think about just going head to head with those and making the best. I think we already have enough data now from a Kodiak study that says that IL-6 doesn't likely add anything in wet AMD. So I think that maybe you sort of take that off the table. Based on that data that IL-6 doesn't seem to provide any additive benefit, you know, the most natural positioning for something that has an anti-inflammatory effect is in something called uveitic macular edema or non-infectious uveitis, and most retinal specialists would tell you a portion of their DME patients have a more inflammatory-driven disease. Now, identifying those with the baseline characteristic becomes a little more challenging for a clinical trial, but that's how we would think about 8143 is. Complementing 8141, assuming 8141 continues to advance, and targeting it towards, naturally, diseases that are retinal vascular diseases, that includes retinal vein occlusion, potentially, that are more driven by inflammation.
Correct. Very good. Helpful. Final question. How is the financial, what is the financial position, cash, bond rate?
So we just disclosed when we announced the first patient dose that we had received the second tranche of a pipe deal that we had done in 2025. Until we had the IND open, you know, I think it wasn't certain that we would receive all that money, so that was important to get the full $95 million from that. We also announced that we had about $29 million in proceeds from an ATM purchases last quarter, so that gives us about $220 million, which will take us into 2029.
Oh, very good. Well, very good. Craig, that's all I have for you. Appreciate it. Thank you.
Always good to see you.
Likewise.
0:02 to 26:43 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Welcome, everyone. Yatin Suneza from Guggenheim. My pleasure to host Craig Parker, the CEO of Surosan here. We will be chatting for the next, let's say, 25, 30 minutes. Craig, thank you so much. We always appreciate your presence and you coming, spending time with us. Why don't you make some opening comments? You know…
Craig Parker: Yeah, it's a very exciting time for Wnt Biology, exciting time for retina broadly, retinal vascular diseases broadly. So the background of Surizen is we actually started as a Wnt Biology-focused company. We discovered the multifunctional antibodies that we've…